Kiora Pharmaceuticals (NASDAQ: KPRX) announced that the results of its Phase 1 ABACUS‑1 study of the retinal photoswitch KIO‑301 have been published in the journal Nature Medicine.
Continue reading for full analysis...
Kiora Pharmaceuticals, Inc. (KPRX) completed a private placement that raised up to $24 million, consisting of $5 million in upfront cash and up to $19 million from the exercise of milestone‑based warrants. The transaction closed on April 6, 2026, and the company announced the completion on April 7, 2026.
Continue reading for full analysis...